NVS — NOVARTIS AG
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1114448 ·
Last close
$142.57
Market Cap
$270.98B
52W High
$165.43
52W Low
$117.98
ADV30
2,278,488
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,951,000,000 | 11,241,000,000 | 4,750,000,000 | 3,264,000,000 | 122,033,000,000 | 7,616,000,000 | 80,087,000,000 |
| Mar 2026 | 13,524,000,000 | 10,065,000,000 | 4,235,000,000 | 3,156,000,000 | 118,532,000,000 | 6,877,000,000 | 79,605,000,000 |
| Dec 2025 | 13,860,000,000 | 10,249,000,000 | 3,616,000,000 | 2,409,000,000 | 110,949,000,000 | 11,435,000,000 | 64,400,000,000 |
| Sep 2025 | 14,358,000,000 | 10,819,000,000 | 4,501,000,000 | 3,928,000,000 | 107,289,000,000 | 9,556,000,000 | 62,537,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$18,393,000,000
Investing CF
$-17,805,000,000
Financing CF
$453,000,000
CapEx
$-3,413,000,000
Dividends Paid
$-11,553,000,000
Buybacks
$-6,856,000,000
EPS Diluted TTM
$6.63
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$39,649,000,000
Inventory
$6,220,000,000
Receivables
$9,854,000,000
ST Investments
$74,000,000
EBIT TTM
$16,912,000,000
Pretax Income TTM
$15,522,000,000
Interest Exp TTM
$1,390,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,692,998,144
EBITDA
$23,097,999,360
Free Cash Flow
$11,900,250,112
Enterprise Value
$302,502,051,840
Total Cash
$7,617,999,872
Total Debt
$49,014,001,664
Shares Out
1,900,714,840
Trailing EPS
$6.62
Book Value
$21.86
ROE
30.3%
ROA
10.2%
Div Yield
3.46%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 56,674,000,000 | 17,644,000,000 | 13,984,000,000 | 110,949,000,000 | 64,400,000,000 | 46,130,000,000 | 19,144,000,000 |
| Dec 2024 | 51,722,000,000 | 14,544,000,000 | 11,941,000,000 | 102,246,000,000 | 58,120,000,000 | 44,046,000,000 | 17,619,000,000 |
| Dec 2023 | 46,660,000,000 | 9,769,000,000 | 14,850,000,000 | 99,945,000,000 | 53,195,000,000 | 46,667,000,000 | 14,458,000,000 |
| Dec 2022 | 43,461,000,000 | 7,946,000,000 | 6,955,000,000 | 117,453,000,000 | 58,030,000,000 | 59,342,000,000 | 14,236,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.84
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $160.00 · spot: $142.57 · call volume: 177 · put volume: 1,252
Expected Move to 2026-11-20:
±$11.68
(8.19%) —
implied range
$130.89 –
$154.25
· ATM straddle on $145.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVSEF | NOVARTIS AG | $267.87B | $140.93 | — |
| AZN | ASTRAZENECA PLC | $250.42B | $161.47 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| ABT | ABBOTT LABORATORIES | $171.01B | $98.83 | — |
| PFE | PFIZER INC | $162.55B | $28.52 | — |
News headlines (Yahoo Finance, 1h cache)
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
2026-09-30 08:47 · Yahoo
CAS announces collaboration with Novartis to advance AI-ready reaction informatics
2026-09-29 12:00 · Yahoo
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?
2026-09-28 23:21 · Yahoo
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
2026-09-26 01:25 · Yahoo
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
2026-09-25 23:21 · Yahoo
Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline
2026-09-25 01:13 · Yahoo
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
2026-09-30 13:40 · Yahoo
ARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Board
2026-09-29 07:00 · Yahoo
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
2026-09-26 01:02 · Yahoo
Rezolv secures up to $636m for 1.3GWp Dama Solar project in Romania
2026-10-01 08:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.